Novo Nordisk (NVO) has released an update.
Novo Nordisk reported an impressive 23% increase in sales to DKK 204.7 billion for the first nine months of 2024, driven by strong demand for its diabetes and obesity treatments. Operating profit also rose by 21%, reflecting robust performance in North America and international markets. The company continues to innovate with advancements in its semaglutide portfolio and new developments in obesity care.
For further insights into NVO stock, check out TipRanks’ Stock Analysis page.
